

Supplementary Table 5. Influence of immune infiltrated and stroma markers on overall survival in different lymphatic metastatic status (n=359)

Characteristics	Stratification	Lymph node positive			Lymph node negative		
		mOS (95% CI)	χ^2	P-value	mOS (95% CI)	χ^2	P-value
CD3	Low	8.90 (7.60–11.30)	2.48	0.115	20.90 (14.80–34.70)	8.14	0.004
	High	11.70 (8.60–22.90)			42.80 (28.90–61.70)		
CD4	Low	9.85 (8.30–13.50)	0.6	0.438	24.10 (17.30–29.90)	14.16	<0.001
	High	11.70 (8.10–20.60)			55.50 (32.80–87.60)		
CD8	Low	11.05 (8.30–13.90)	0	0.956	24.10 (17.20–31.30)	15.31	<0.001
	High	10.00 (5.30–18.40)			55.50 (30.10–NA)		
Foxp3	Low	9.10 (8.30–16.20)	0.12	0.725	36.90 (36.90–49.90)	3.4	0.065
	High	11.35 (8.10–13.50)			23.10 (14.80–41.80)		
CD68	Low	10.90 (8.30–10.90)	0.01	0.923	46.80 (28.90–61.40)	6	0.014
	High	9.9 (6.20–20.60)			23.10 (16.40–30.10)		
CD66b	Low	11.30 (8.70–16.20)	9.23	0.002	39.60 (28.90–49.90)	6.4	0.011
	High	6.05 (0.20–10.00)			17.9 (9.60–26.90)		
Stroma	Dormant	11.9 (0.10–NA)	1.85	0.605	NA (49.90–NA)	18.94	<0.001
	Fibrogenic	10.6 (8.30–20.60)			26.90 (20.20–53.50)		
	Inert	11.15 (5.90–12.30)			27.00 (17.30–42.20)		
	Fibrolytic	9.70 (3.30–12.30)			23.40 (14.80–30.10)		

CI, confidence interval; mOS, median overall survival.